Nuclear medicine society SNM of Reston, VA, announced that its Clinical Trials Network has expanded its membership with several European commercial providers of PET radiopharmaceuticals.
Advanced Accelerator Applications of Saint Genis Pouilly, France; Erigal Limited of South London and Dublin; and IBA Molecular, a division of Belgian radiopharmaceutical firm Ion Beam Application (IBA), have all joined the network, SNM said. The three companies represent 27 PET manufacturing sites in Europe.
The SNM Clinical Trials Network has received investigational new drug (IND) status for the use of fluorothymidine in multicenter studies. The goal of the network is to receive multicenter IND status for additional imaging biomarkers over time. Advanced Accelerator Applications, Erigal Limited, and IBA Molecular have all expressed interest in participating in future multicenter clinical trials under SNM INDs, according to SNM.
There are currently 201 manufacturing sites registered with the network worldwide, with 23% located in European regions, SNM said.
Related Reading
SNM awards research grants, July 8, 2009
Society of Nuclear Medicine issues Medical Isotope Communiqué, June 16, 2009
Moly crisis overshadows SNM Image of the Year award, June 15, 2009
SNM poll: Isotope shortage affecting users, procedures, June 15, 2009
Canadian health minister meets SNM execs, June 15, 2009
Copyright © 2009 AuntMinnie.com
